Sudden Cardiac Arrest in Young Athletes: What the Evidence Tells Us — and What We Can Do About It

---

Few things in medicine carry the emotional weight of a young athlete collapsing on a field. Sudden cardiac arrest (SCA) in this population is rare — but when it happens, it is catastrophic, and the question that always follows is whether it could have been prevented. That question is at the center of an ongoing and genuinely complex debate in the United States, and as the providers who know these kids best, you are an important part of the answer.

The Limits of the Current Standard

You know this scenario well: the seasonal surge of sports clearance visits, each one a brief window to assess a healthy-appearing teenager before clearing them to compete. The pre-participation physical examination (PPE), anchored by the AHA’s 14-element cardiac history and physical, is the established standard for this evaluation. It is not without value — it identifies athletes with known conditions, prompts important family history conversations, and screens for obvious abnormalities on exam.

But the evidence on its limitations is difficult to ignore. The cardiac conditions most commonly linked to SCA in young athletes — hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, coronary anomalies, and primary electrical disorders such as Long QT syndrome and Wolff-Parkinson-White — are frequently asymptomatic and produce no physical exam findings. No murmur. No family history red flag. No symptom that would trigger concern. Studies have consistently shown that the PPE alone misses a substantial proportion of at-risk athletes, and the argument for augmenting it is well-supported by the data.

Understanding the Causes: A Clearer Picture Is Emerging

Our understanding of what causes SCA in young athletes has evolved significantly — and that evolution matters for how we think about screening. For years, hypertrophic cardiomyopathy (HCM) was considered the dominant cause. More recent analysis suggests a more nuanced picture. The unifying mechanism in virtually every case is a fatal arrhythmia, but what drives that arrhythmia varies considerably.

Structural causes — primarily cardiomyopathies and coronary anomalies — account for a significant portion of identified cases. HCM and arrhythmogenic cardiomyopathy are among the most common, with coronary anomalies representing another meaningful subset. But approximately 35–40% of SCA cases in young athletes have no identifiable cause on current evaluation. It is plausible that some of those cases involve primary electrical disorders — arrhythmia syndromes that leave no structural footprint and therefore go undetected on autopsy, which is where the majority of causal data comes from. How many is genuinely unknown, and the science here continues to evolve.

What we do know is that several primary electrical disorders — including Long QT syndrome, Brugada syndrome, WPW, and others — can be identified on a resting ECG, and these are conditions a standard physical exam will not detect. An ECG will not identify every arrhythmia risk; some conditions, by their nature, only manifest under specific circumstances. But it adds a meaningful and evidence-supported layer of evaluation that the PPE simply cannot replicate — and combined with an echocardiogram to evaluate for structural disease, the two tests together address the broadest range of identifiable risk factors currently available in a non-invasive screen.

What ECG and Echocardiogram Add

The 12-lead ECG is the most effective tool available for identifying athletes with primary electrical disorders and can also provide important evidence of cardiomyopathy and other structural disease. The European Society of Cardiology has recommended ECG as a component of pre-participation screening for decades, and programs that have implemented ECG-inclusive screening — most notably Italy’s national program, in place since 1982 — have demonstrated a measurable reduction in SCA rates. Data from those programs consistently shows ECG outperforming the history and physical examination by a significant margin in identifying at-risk athletes. Professional sports organizations — the NBA, NFL, and most major leagues — require ECG as a minimum standard for their athletes. It is a reasonable bar for our patients as well.

Echocardiography adds structural detail that an ECG cannot provide. It is the gold standard for diagnosing hypertrophic cardiomyopathy, dilated cardiomyopathy, and valvular disease, and it is also the best tool we have for evaluating coronary anomalies — the second most common structural cause of SCA in young athletes. It takes longer and costs more than an ECG, but when the goal is the most comprehensive non-invasive cardiac screen available, echo and ECG together represent the current standard of care in high-performance athletics.

The Debate — and Why It Does Not Apply to Individual Patients

The arguments against universal mandatory ECG and echo screening are not without merit — at the population level. SCA is rare. Implementing large-scale screening programs is expensive. Access to qualified interpreters is uneven. False positives carry real costs: anxiety, delayed return to play, and downstream testing. These are legitimate systemic considerations, and they explain why the AHA has stopped short of mandating ECG in the PPE.

But those arguments address a policy question, not a clinical one. For the family sitting across from you asking whether there is more they can do — the answer is yes, and the case for it is strong. The rarity of SCA is not reassuring to the family whose child is the rare case. And for a parent who wants the most thorough available screening for their child before a season of competitive athletics, the evidence clearly supports offering it.

What We Offer — and How to Direct Families to Us

Because these screenings are not covered by insurance for asymptomatic athletes, we offer them as flat-rate, self-pay services — priced to be accessible to families who want to take a proactive step.

A Resource for Families

We know that the sports clearance visit is not always the right moment for a detailed conversation about cardiac screening. For families who want to learn more on their own time, we have created a plain-language summary at:

No screening is perfect — we are always transparent with families about that. But the evidence is clear that ECG and echocardiogram meaningfully outperform the PPE alone in identifying athletes at risk. Giving families access to that information, and to the testing, is the right thing to do. We are here to make that as easy as possible for you and for them.